A New Approach to Generating Medical Isotopes
Molybdenum-99 (Mo-99), the most widely-used medical isotope, decays into technetium-99m, which is used in more than 40 million medical diagnostic procedures annually. The supply chain for this essential isotope is at risk, with very few production sites that have struggled with reliability in the past. Current production methods are also inefficient and use highly enriched uranium as the source material, a proliferation risk. SHINE was founded to address these concerns and rethink the way we produce Mo-99 and the way we approach commercial nuclear projects in general. This presentation will cover SHINE’s innovative liquid target subcritical assembly design, the engineering challenges of this design, and how the SHINE team approaches these challenges.
Bio: Tracy Radel is the VP of Engineering for SHINE Medical Technologies. SHINE is dedicated to being the world leader in the safe, clean, affordable production of medical tracers and cancer treatment elements. Construction of their Moly-99 production facility began last fall and Tracy leads the team of approximately 40 engineers responsible for the design, procurement, installation, and testing of all production facility equipment. Tracy is also the design authority for the facility and serves as the lead technical interface with the Nuclear Regulatory Commission.
